What is Cagrilintide?
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, designed to work alongside GLP-1 agonists for enhanced metabolic research. Amylin is a hormone co-secreted with insulin from pancreatic beta cells that promotes satiety, delays gastric emptying, and suppresses glucagon secretion.
Mechanism of Action
Cagrilintide binds to amylin receptors (calcitonin receptor + RAMP complexes) in the brain, activating distinct satiety pathways that complement GLP-1 signaling. This provides a second “brake” on appetite through a non-overlapping pathway.
CagriSema: The Combination Approach
The most notable research application is “CagriSema” — cagrilintide combined with semaglutide. Phase 2/3 trials show that the amylin + GLP-1 combination produces greater metabolic effects than either alone, demonstrating the power of multi-pathway approaches.
Comparison with Other Approaches
While tirzepatide and retatrutide add receptors to the GLP-1 framework (GIP, glucagon), CagriSema takes a different approach: combining two separate hormones that control different aspects of energy balance.
For research and educational purposes only. Catalog | COAs
Related Articles
All products are sold strictly for research purposes only. Not for human consumption.